US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk
Today 19:59
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk Oct 26 (Reuters) - A U.S. court on Monday allowed Eli Lilly LLY.N to continue weight-loss drug advertisements that rival Novo Nordisk NOVOb.CO claimed were false and misleading.
(Reporting by Jonathan Stempel in New York)
(((( jon.stempel@thomsonreuters.com ; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net /))))
Recent news on Novo Nordisk A/S
See all newsUS judge won't block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk (updated)
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk
CVS is trying out pharmacists in chronic health management
Brief: FDA Approves Awiqli First Once-Weekly Insulin For Type 2 Diabetes Mellitus In Pediatric Patients
Dr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit